White Paper: New European Health Technology Assessment Regulation

In December 2021, the European Commission adopted the new European Health Technology Assessment Regulation, requiring clinical submissions at the European level, nearly four years after it was initially proposed in January 2018. Ultimately aimed at strengthening cooperation among European HTA agencies, the new regulation will have a progressive implementation, from 2025 to 2030.

The European Health Technology Assessment Regulation is now in place, making it mandatory for manufacturers to submit a clinical dossier at European level from 2025.

It’s important for pharma, biotech and medtech companies to be aware of this new joint assessment methodology (including type of comparators, evidence requested, and stakeholders involved) to understand the level of effort for the joint work by Member States – and what effect that has on access to new medicine.

In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.

Publications
Published on:
August 4, 2022
Written by:
Nerea Blanqué-Catalina, Marta Aguado

Do you have any questions about the white paper “New European Health Technology Assessment Regulation”?

Related news

Publications November 22, 2022
External Control Arms: The Way to Go?
The growing implementation of Single Arm Trials (SATs) with External Control Arms (ECAs) has been the subject of heated debate across Europe.
Clinical Trials Regulatory
Multimedia October 27, 2022
RARECast: Leveraging Technology to Empower Patients and Decentralize Clinical Trials
Technology plays a central role in the future of patient empowerment and decentralized clinical trials. Listen to the podcast to learn more.
Decentralized Clinical Trials MedTech
Multimedia October 13, 2022
Exclusive MedTech Webinar Series “Expanding Beyond APAC”
Join this series of webinars to learn about the strategies, challenges, and best practices of scaling beyond the Asia Pacific MedTech market.
MedTech
Events October 7, 2022
Debate Sobre los IPT en Oncología
We are pleased to announce our next event, “Debate Sobre los IPT en Oncología,” focusing on price and reimbursement (P&R) of vital oncology and oncohematology therapies.
Market Access Product Development Regulatory
Events October 6, 2022
The MedTech Conference 2022
We are pleased to share that we will be joining the MedTech Conference 2022 as sponsors and speakers! This year’s edition will have more than 100 sessions focusing on today’s hot topics.
M&A MedTech Regulatory
News October 4, 2022
Alira Health enhances its market access services through a strategic partnership with Centivis
Alira Health, a global healthcare advisory and technology company, announced a strategic partnership with Centivis AG, a boutique market access consulting agency, specializing in digital(...)
Digital Health Market Access MedTech Pharma Regulatory
Multimedia September 29, 2022
Webinar Replay: Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.